BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//AssetMemo//Readout calendar//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:Sichuan Baili Pharmaceutical readouts · AssetMemo
X-WR-CALDESC:Upcoming readouts of studies Sichuan Baili Pharmaceutical's dr
 ugs run\, from ClinicalTrials.gov estimates.
REFRESH-INTERVAL;VALUE=DURATION:PT12H
X-PUBLISHED-TTL:PT12H
BEGIN:VEVENT
UID:NCT06668961-2065@assetmemo.bio
DTSTAMP:20261121T005012Z
DTSTART;VALUE=DATE:20261130
DTEND;VALUE=DATE:20261201
SUMMARY:Danvilostomig: Phase 2 readout est. (NCT06668961)
DESCRIPTION:Danvilostomig\, phase 2\, Head and Neck Squamous Cell Carcinoma
 .\nStudy: A Study of SI-B001+SI-B003 Combined With Platinum-based Chemothe
 rapy as First-line Treatment in Patients With Recurrent or Metastatic Head
  and Neck Squamous Cell Carcinoma\nEstimated primary completion: November 
 2026. This is a ClinicalTrials.gov estimate\, not a confirmed readout date
 \, and it can move.\nDrug page: https://assetmemo.bio/drug/danvilostomig#u
 pcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT06668
 961
URL:https://assetmemo.bio/drug/danvilostomig#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06118333-2044@assetmemo.bio
DTSTAMP:20261121T005012Z
DTSTART;VALUE=DATE:20261130
DTEND;VALUE=DATE:20261201
SUMMARY:Izalontamab brengitecan: Phase 3 readout est. (NCT06118333)
DESCRIPTION:Izalontamab brengitecan\, phase 3\, Nasopharyngeal Carcinoma.\n
 Study: A Study Comparing BL-B01D1 With Physician's Choice of Chemotherapy 
 in Patients With Recurrent or Metastatic Nasopharyngeal Carcinoma(PANKU-NP
 C01)\nEstimated primary completion: November 2026. This is a ClinicalTrial
 s.gov estimate\, not a confirmed readout date\, and it can move.\nDrug pag
 e: https://assetmemo.bio/drug/izalontamab-brengitecan#upcoming-events\nReg
 istry record: https://clinicaltrials.gov/study/NCT06118333
URL:https://assetmemo.bio/drug/izalontamab-brengitecan#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05668858-2065@assetmemo.bio
DTSTAMP:20261121T005012Z
DTSTART;VALUE=DATE:20261231
DTEND;VALUE=DATE:20270101
SUMMARY:Danvilostomig: Phase 1/2 readout est. (NCT05668858)
DESCRIPTION:Danvilostomig\, phase 1/2\, Head and Neck Squamous Cell Carcino
 ma.\nStudy: A Study of SI-B001+SI-B003± Chemotherapy in Patients With Loc
 ally Advanced or Metastatic Head and Neck Squamous Cell Carcinoma\nEstimat
 ed primary completion: December 2026. This is a ClinicalTrials.gov estimat
 e\, not a confirmed readout date\, and it can move.\nDrug page: https://as
 setmemo.bio/drug/danvilostomig#upcoming-events\nRegistry record: https://c
 linicaltrials.gov/study/NCT05668858
URL:https://assetmemo.bio/drug/danvilostomig#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05949606-2065@assetmemo.bio
DTSTAMP:20261121T005012Z
DTSTART;VALUE=DATE:20261231
DTEND;VALUE=DATE:20270101
SUMMARY:Danvilostomig: Phase 1/2 readout est. (NCT05949606)
DESCRIPTION:Danvilostomig\, phase 1/2\, Non-Small Cell Lung Cancer.\nStudy:
  A Study of SI-B001+SI-B003± Chemotherapy in the Treatment of Locally Adv
 anced or Metastatic Non-small Cell Lung Cancer\nEstimated primary completi
 on: December 2026. This is a ClinicalTrials.gov estimate\, not a confirmed
  readout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/da
 nvilostomig#upcoming-events\nRegistry record: https://clinicaltrials.gov/s
 tudy/NCT05949606
URL:https://assetmemo.bio/drug/danvilostomig#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06114511-2282@assetmemo.bio
DTSTAMP:20261121T005012Z
DTSTART;VALUE=DATE:20261231
DTEND;VALUE=DATE:20270101
SUMMARY:Trastuzumab brengitecan: Phase 1/2 readout est. (NCT06114511)
DESCRIPTION:Trastuzumab brengitecan\, phase 1/2\, Non-Small Cell Lung Cance
 r.\nStudy: A Study of BL-M07D1 in Patients With HER2-Overexpressing or HER
 2-Mutant Locally Advanced or Metastatic Non-Small Cell Lung Cancer\nEstima
 ted primary completion: December 2026. This is a ClinicalTrials.gov estima
 te\, not a confirmed readout date\, and it can move.\nDrug page: https://a
 ssetmemo.bio/drug/trastuzumab-brengitecan#upcoming-events\nRegistry record
 : https://clinicaltrials.gov/study/NCT06114511
URL:https://assetmemo.bio/drug/trastuzumab-brengitecan#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05803018-2044@assetmemo.bio
DTSTAMP:20261121T005012Z
DTSTART;VALUE=DATE:20261231
DTEND;VALUE=DATE:20270101
SUMMARY:Izalontamab brengitecan: Phase 1/2 readout est. (NCT05803018)
DESCRIPTION:Izalontamab brengitecan\, phase 1/2.\nStudy: A Study of BL-B01D
 1 in Patients With Multiple Solid Tumors\, Including Recurrent or Metastat
 ic Gynecological Malignancies\nEstimated primary completion: December 2026
 . This is a ClinicalTrials.gov estimate\, not a confirmed readout date\, a
 nd it can move.\nDrug page: https://assetmemo.bio/drug/izalontamab-brengit
 ecan#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NC
 T05803018
URL:https://assetmemo.bio/drug/izalontamab-brengitecan#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06031584-2282@assetmemo.bio
DTSTAMP:20261121T005012Z
DTSTART;VALUE=DATE:20261231
DTEND;VALUE=DATE:20270101
SUMMARY:Trastuzumab brengitecan: Phase 1/2 readout est. (NCT06031584)
DESCRIPTION:Trastuzumab brengitecan\, phase 1/2.\nStudy: A Study of BL-M07D
 1 in Patients With a Variety of Solid Tumors Including Locally Advanced or
  Metastatic HER2-positive/Low-expressing Urinary and Gastrointestinal Tumo
 rs\nEstimated primary completion: December 2026. This is a ClinicalTrials.
 gov estimate\, not a confirmed readout date\, and it can move.\nDrug page:
  https://assetmemo.bio/drug/trastuzumab-brengitecan#upcoming-events\nRegis
 try record: https://clinicaltrials.gov/study/NCT06031584
URL:https://assetmemo.bio/drug/trastuzumab-brengitecan#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06066203-3107@assetmemo.bio
DTSTAMP:20261121T005012Z
DTSTART;VALUE=DATE:20261231
DTEND;VALUE=DATE:20270101
SUMMARY:Nebratamig: Phase 1/2 readout est. (NCT06066203)
DESCRIPTION:Nebratamig\, phase 1/2.\nStudy: A Study of GNC-035 in Relapsed 
 or Refractory Non-Hodgkin 's Lymphoma and Other Hematological Malignancies
 \nEstimated primary completion: December 2026. This is a ClinicalTrials.go
 v estimate\, not a confirmed readout date\, and it can move.\nDrug page: h
 ttps://assetmemo.bio/drug/nebratamig#upcoming-events\nRegistry record: htt
 ps://clinicaltrials.gov/study/NCT06066203
URL:https://assetmemo.bio/drug/nebratamig#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05054439-2265@assetmemo.bio
DTSTAMP:20261121T005012Z
DTSTART;VALUE=DATE:20261231
DTEND;VALUE=DATE:20270101
SUMMARY:Izalontamab: Phase 2 readout est. (NCT05054439)
DESCRIPTION:Izalontamab\, phase 2\, Head and Neck Squamous Cell Carcinoma.\
 nStudy: A Clinical Study of SI-B001 in Combination With Paclitaxel/Docetax
 el in the Treatment of Recurrent and Metastatic HNSCC\nEstimated primary c
 ompletion: December 2026. This is a ClinicalTrials.gov estimate\, not a co
 nfirmed readout date\, and it can move.\nDrug page: https://assetmemo.bio/
 drug/izalontamab#upcoming-events\nRegistry record: https://clinicaltrials.
 gov/study/NCT05054439
URL:https://assetmemo.bio/drug/izalontamab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05785039-2044@assetmemo.bio
DTSTAMP:20261121T005012Z
DTSTART;VALUE=DATE:20261231
DTEND;VALUE=DATE:20270101
SUMMARY:Izalontamab brengitecan: Phase 2 readout est. (NCT05785039)
DESCRIPTION:Izalontamab brengitecan\, phase 2.\nStudy: A Study of BL-B01D1 
 in Patients With Multiple Solid Tumors\, Including Locally Advanced or Met
 astatic Urinary System Tumors\nEstimated primary completion: December 2026
 . This is a ClinicalTrials.gov estimate\, not a confirmed readout date\, a
 nd it can move.\nDrug page: https://assetmemo.bio/drug/izalontamab-brengit
 ecan#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NC
 T05785039
URL:https://assetmemo.bio/drug/izalontamab-brengitecan#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05924841-2044@assetmemo.bio
DTSTAMP:20261121T005012Z
DTSTART;VALUE=DATE:20261231
DTEND;VALUE=DATE:20270101
SUMMARY:Izalontamab brengitecan: Phase 2 readout est. (NCT05924841)
DESCRIPTION:Izalontamab brengitecan\, phase 2.\nStudy: A Study of BL-B01D1\
 , SI-B003 and BL-B01D1+SI-B003 in Patients With Extensive Stage Small Cell
  Lung Cancer\nEstimated primary completion: December 2026. This is a Clini
 calTrials.gov estimate\, not a confirmed readout date\, and it can move.\n
 Drug page: https://assetmemo.bio/drug/izalontamab-brengitecan#upcoming-eve
 nts\nRegistry record: https://clinicaltrials.gov/study/NCT05924841
URL:https://assetmemo.bio/drug/izalontamab-brengitecan#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05956587-2044@assetmemo.bio
DTSTAMP:20261121T005012Z
DTSTART;VALUE=DATE:20261231
DTEND;VALUE=DATE:20270101
SUMMARY:Izalontamab brengitecan: Phase 2 readout est. (NCT05956587)
DESCRIPTION:Izalontamab brengitecan\, phase 2\, Non-Small Cell Lung Cancer.
 \nStudy: A Study of SI-B003 and BL-B01D1+SI-B003 in Patients With Locally 
 Advanced or Metastatic Non-small Cell Lung Cancer\, Nasopharyngeal Carcino
 ma and Other Solid Tumors\nEstimated primary completion: December 2026. Th
 is is a ClinicalTrials.gov estimate\, not a confirmed readout date\, and i
 t can move.\nDrug page: https://assetmemo.bio/drug/izalontamab-brengitecan
 #upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT059
 56587
URL:https://assetmemo.bio/drug/izalontamab-brengitecan#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05965856-2044@assetmemo.bio
DTSTAMP:20261121T005012Z
DTSTART;VALUE=DATE:20261231
DTEND;VALUE=DATE:20270101
SUMMARY:Izalontamab brengitecan: Phase 2 readout est. (NCT05965856)
DESCRIPTION:Izalontamab brengitecan\, phase 2\, Urothelial Carcinoma.\nStud
 y: A Study of SI-B003 and BL-B01D1+SI-B003 in Patients With Locally Advanc
 ed or Metastatic Urothelial Carcinoma and Other Solid Tumors\nEstimated pr
 imary completion: December 2026. This is a ClinicalTrials.gov estimate\, n
 ot a confirmed readout date\, and it can move.\nDrug page: https://assetme
 mo.bio/drug/izalontamab-brengitecan#upcoming-events\nRegistry record: http
 s://clinicaltrials.gov/study/NCT05965856
URL:https://assetmemo.bio/drug/izalontamab-brengitecan#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05990803-2044@assetmemo.bio
DTSTAMP:20261121T005012Z
DTSTART;VALUE=DATE:20261231
DTEND;VALUE=DATE:20270101
SUMMARY:Izalontamab brengitecan: Phase 2 readout est. (NCT05990803)
DESCRIPTION:Izalontamab brengitecan\, phase 2.\nStudy: A Study of BL-B01D1\
 , SI-B003 and BL-B01D1+SI-B003 in Patients With Recurrent or Metastatic Ce
 rvical Cancer and Other Gynecological Malignancies\nEstimated primary comp
 letion: December 2026. This is a ClinicalTrials.gov estimate\, not a confi
 rmed readout date\, and it can move.\nDrug page: https://assetmemo.bio/dru
 g/izalontamab-brengitecan#upcoming-events\nRegistry record: https://clinic
 altrials.gov/study/NCT05990803
URL:https://assetmemo.bio/drug/izalontamab-brengitecan#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06006169-2044@assetmemo.bio
DTSTAMP:20261121T005012Z
DTSTART;VALUE=DATE:20261231
DTEND;VALUE=DATE:20270101
SUMMARY:Izalontamab brengitecan: Phase 2 readout est. (NCT06006169)
DESCRIPTION:Izalontamab brengitecan\, phase 2.\nStudy: A Study of BL-B01D1\
 , SI-B003 and BL-B01D1+SI-B003 in Patients With Recurrent or Metastatic He
 ad and Neck Squamous Cell Carcinoma and Other Solid Tumors\nEstimated prim
 ary completion: December 2026. This is a ClinicalTrials.gov estimate\, not
  a confirmed readout date\, and it can move.\nDrug page: https://assetmemo
 .bio/drug/izalontamab-brengitecan#upcoming-events\nRegistry record: https:
 //clinicaltrials.gov/study/NCT06006169
URL:https://assetmemo.bio/drug/izalontamab-brengitecan#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06008054-2044@assetmemo.bio
DTSTAMP:20261121T005012Z
DTSTART;VALUE=DATE:20261231
DTEND;VALUE=DATE:20270101
SUMMARY:Izalontamab brengitecan: Phase 2 readout est. (NCT06008054)
DESCRIPTION:Izalontamab brengitecan\, phase 2.\nStudy: A Study of SI-B003\,
  BL-B01D1+SI-B003 and BL-B01D1+PD-1 Monoclonal Antibody in Patients With L
 ocally Advanced or Metastatic Esophageal Cancer\, Gastric Cancer\, Colorec
 tal Cancer and Other Gastrointestinal Tumors\nEstimated primary completion
 : December 2026. This is a ClinicalTrials.gov estimate\, not a confirmed r
 eadout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/izal
 ontamab-brengitecan#upcoming-events\nRegistry record: https://clinicaltria
 ls.gov/study/NCT06008054
URL:https://assetmemo.bio/drug/izalontamab-brengitecan#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06042894-2044@assetmemo.bio
DTSTAMP:20261121T005012Z
DTSTART;VALUE=DATE:20261231
DTEND;VALUE=DATE:20270101
SUMMARY:Izalontamab brengitecan: Phase 2 readout est. (NCT06042894)
DESCRIPTION:Izalontamab brengitecan\, phase 2\, HR+/HER2- Metastatic Breast
  Cancer.\nStudy: A Study of SI-B003 or BL-B01D1+SI-B003 in Patients With U
 nresectable Locally Advanced or Recurrent Metastatic HER2 Negative Breast 
 Cancer\nEstimated primary completion: December 2026. This is a ClinicalTri
 als.gov estimate\, not a confirmed readout date\, and it can move.\nDrug p
 age: https://assetmemo.bio/drug/izalontamab-brengitecan#upcoming-events\nR
 egistry record: https://clinicaltrials.gov/study/NCT06042894
URL:https://assetmemo.bio/drug/izalontamab-brengitecan#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06405425-2044@assetmemo.bio
DTSTAMP:20261121T005012Z
DTSTART;VALUE=DATE:20261231
DTEND;VALUE=DATE:20270101
SUMMARY:Izalontamab brengitecan: Phase 2 readout est. (NCT06405425)
DESCRIPTION:Izalontamab brengitecan\, phase 2\, Urothelial Carcinoma.\nStud
 y: A Study of BL-B01D1 + PD-1 in Patients With Locally Advanced or Metasta
 tic Urothelial Carcinoma\nEstimated primary completion: December 2026. Thi
 s is a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it
  can move.\nDrug page: https://assetmemo.bio/drug/izalontamab-brengitecan#
 upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT0640
 5425
URL:https://assetmemo.bio/drug/izalontamab-brengitecan#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06437509-2044@assetmemo.bio
DTSTAMP:20261121T005012Z
DTSTART;VALUE=DATE:20261231
DTEND;VALUE=DATE:20270101
SUMMARY:Izalontamab brengitecan: Phase 2 readout est. (NCT06437509)
DESCRIPTION:Izalontamab brengitecan\, phase 2.\nStudy: A Study of BL-B01D1+
 PD-1 Monoclonal Antibody in Patients With Extensive-stage Small Cell Lung 
 Cancer\nEstimated primary completion: December 2026. This is a ClinicalTri
 als.gov estimate\, not a confirmed readout date\, and it can move.\nDrug p
 age: https://assetmemo.bio/drug/izalontamab-brengitecan#upcoming-events\nR
 egistry record: https://clinicaltrials.gov/study/NCT06437509
URL:https://assetmemo.bio/drug/izalontamab-brengitecan#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06471205-2044@assetmemo.bio
DTSTAMP:20261121T005012Z
DTSTART;VALUE=DATE:20261231
DTEND;VALUE=DATE:20270101
SUMMARY:Izalontamab brengitecan: Phase 2 readout est. (NCT06471205)
DESCRIPTION:Izalontamab brengitecan\, phase 2.\nStudy: A Study of BL-B01D1+
 PD-1 Monoclonal Antibody in Patients With Unresectable Locally Advanced or
  Recurrent Metastatic Triple-negative Breast Cancer\nEstimated primary com
 pletion: December 2026. This is a ClinicalTrials.gov estimate\, not a conf
 irmed readout date\, and it can move.\nDrug page: https://assetmemo.bio/dr
 ug/izalontamab-brengitecan#upcoming-events\nRegistry record: https://clini
 caltrials.gov/study/NCT06471205
URL:https://assetmemo.bio/drug/izalontamab-brengitecan#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06382129-2044@assetmemo.bio
DTSTAMP:20261121T005012Z
DTSTART;VALUE=DATE:20261231
DTEND;VALUE=DATE:20270101
SUMMARY:Izalontamab brengitecan: Phase 3 readout est. (NCT06382129)
DESCRIPTION:Izalontamab brengitecan\, phase 3\, Non-Small Cell Lung Cancer.
 \nStudy: A Study Comparing BL-B01D1 With Docetaxel in Patients With Unrese
 ctable Locally Advanced or Metastatic EGFR Wild-type Non-small Cell Lung C
 ancer(PANKU-Lung02)\nEstimated primary completion: December 2026. This is 
 a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it can 
 move.\nDrug page: https://assetmemo.bio/drug/izalontamab-brengitecan#upcom
 ing-events\nRegistry record: https://clinicaltrials.gov/study/NCT06382129
URL:https://assetmemo.bio/drug/izalontamab-brengitecan#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06500026-2044@assetmemo.bio
DTSTAMP:20261121T005012Z
DTSTART;VALUE=DATE:20261231
DTEND;VALUE=DATE:20270101
SUMMARY:Izalontamab brengitecan: Phase 3 readout est. (NCT06500026)
DESCRIPTION:Izalontamab brengitecan\, phase 3.\nStudy: A Study Comparing BL
 -B01D1 With Topotecan in Patients With Recurrent Small Cell Lung Cancer(PA
 NKU-Lung03)\nEstimated primary completion: December 2026. This is a Clinic
 alTrials.gov estimate\, not a confirmed readout date\, and it can move.\nD
 rug page: https://assetmemo.bio/drug/izalontamab-brengitecan#upcoming-even
 ts\nRegistry record: https://clinicaltrials.gov/study/NCT06500026
URL:https://assetmemo.bio/drug/izalontamab-brengitecan#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06131450-2282@assetmemo.bio
DTSTAMP:20261121T005012Z
DTSTART;VALUE=DATE:20270131
DTEND;VALUE=DATE:20270201
SUMMARY:Trastuzumab brengitecan: Phase 1/2 readout est. (NCT06131450)
DESCRIPTION:Trastuzumab brengitecan\, phase 1/2.\nStudy: A Study of BL-M07D
 1 in Patients With Recurrent or Metastatic Gynecologic Malignancies\nEstim
 ated primary completion: January 2027. This is a ClinicalTrials.gov estima
 te\, not a confirmed readout date\, and it can move.\nDrug page: https://a
 ssetmemo.bio/drug/trastuzumab-brengitecan#upcoming-events\nRegistry record
 : https://clinicaltrials.gov/study/NCT06131450
URL:https://assetmemo.bio/drug/trastuzumab-brengitecan#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06962787-2044@assetmemo.bio
DTSTAMP:20261121T005012Z
DTSTART;VALUE=DATE:20270531
DTEND;VALUE=DATE:20270601
SUMMARY:Izalontamab brengitecan: Phase 2 readout est. (NCT06962787)
DESCRIPTION:Izalontamab brengitecan\, phase 2.\nStudy: A Study of BL-B01D1+
 TKI±Pembrolizumab in Patients With Locally Advanced or Metastatic Renal C
 ancer\nEstimated primary completion: May 2027. This is a ClinicalTrials.go
 v estimate\, not a confirmed readout date\, and it can move.\nDrug page: h
 ttps://assetmemo.bio/drug/izalontamab-brengitecan#upcoming-events\nRegistr
 y record: https://clinicaltrials.gov/study/NCT06962787
URL:https://assetmemo.bio/drug/izalontamab-brengitecan#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06978114-2044@assetmemo.bio
DTSTAMP:20261121T005012Z
DTSTART;VALUE=DATE:20270531
DTEND;VALUE=DATE:20270601
SUMMARY:Izalontamab brengitecan: Phase 2 readout est. (NCT06978114)
DESCRIPTION:Izalontamab brengitecan\, phase 2\, Biliary Tract Cancer.\nStud
 y: A Study of BL-B01D1+PD-1/PD-L1 Monoclonal Antibody in Patients With Adv
 anced Biliary Tract Cancer\nEstimated primary completion: May 2027. This i
 s a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it ca
 n move.\nDrug page: https://assetmemo.bio/drug/izalontamab-brengitecan#upc
 oming-events\nRegistry record: https://clinicaltrials.gov/study/NCT0697811
 4
URL:https://assetmemo.bio/drug/izalontamab-brengitecan#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06986785-2044@assetmemo.bio
DTSTAMP:20261121T005012Z
DTSTART;VALUE=DATE:20270531
DTEND;VALUE=DATE:20270601
SUMMARY:Izalontamab brengitecan: Phase 2 readout est. (NCT06986785)
DESCRIPTION:Izalontamab brengitecan\, phase 2.\nStudy: A Study of BL-B01D1 
 Monotherapy\, BL-B01D1 in Combination With Lenvatinib\, BL-B01D1 in Combin
 ation With PD-1 Monoclonal Antibody\, and BL-B01D1 in Combination With PD-
 1 Monoclonal Antibody and Bevacizumab in Patients With Advanced Hepatocell
 ular Carcinoma\nEstimated primary completion: May 2027. This is a Clinical
 Trials.gov estimate\, not a confirmed readout date\, and it can move.\nDru
 g page: https://assetmemo.bio/drug/izalontamab-brengitecan#upcoming-events
 \nRegistry record: https://clinicaltrials.gov/study/NCT06986785
URL:https://assetmemo.bio/drug/izalontamab-brengitecan#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07054567-2044@assetmemo.bio
DTSTAMP:20261121T005012Z
DTSTART;VALUE=DATE:20270531
DTEND;VALUE=DATE:20270601
SUMMARY:Izalontamab brengitecan: Phase 2 readout est. (NCT07054567)
DESCRIPTION:Izalontamab brengitecan\, phase 2.\nStudy: A Study of BL-B01D1 
 + Pembrolizumab ± Bevacizumab in Patients With Recurrent or Metastatic Ce
 rvical Cancer and Endometrial Cancer\nEstimated primary completion: May 20
 27. This is a ClinicalTrials.gov estimate\, not a confirmed readout date\,
  and it can move.\nDrug page: https://assetmemo.bio/drug/izalontamab-breng
 itecan#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/
 NCT07054567
URL:https://assetmemo.bio/drug/izalontamab-brengitecan#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06957886-2282@assetmemo.bio
DTSTAMP:20261121T005012Z
DTSTART;VALUE=DATE:20270531
DTEND;VALUE=DATE:20270601
SUMMARY:Trastuzumab brengitecan: Phase 3 readout est. (NCT06957886)
DESCRIPTION:Trastuzumab brengitecan\, phase 3.\nStudy: A Study of BL-M07D1 
 Versus Investigator's Choice of Chemotherapy in Patients With HER2-low Rec
 urrent/Metastatic Breast Cancer\nEstimated primary completion: May 2027. T
 his is a ClinicalTrials.gov estimate\, not a confirmed readout date\, and 
 it can move.\nDrug page: https://assetmemo.bio/drug/trastuzumab-brengiteca
 n#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT06
 957886
URL:https://assetmemo.bio/drug/trastuzumab-brengitecan#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06498986-2044@assetmemo.bio
DTSTAMP:20261121T005012Z
DTSTART;VALUE=DATE:20270630
DTEND;VALUE=DATE:20270701
SUMMARY:Izalontamab brengitecan: Phase 2 readout est. (NCT06498986)
DESCRIPTION:Izalontamab brengitecan\, phase 2\, Non-Small Cell Lung Cancer.
 \nStudy: A Study of BL-B01D1 in Combination With Osimertinib Mesylate Tabl
 ets in Patients With Locally Advanced or Metastatic Non-small Cell Lung Ca
 ncer\nEstimated primary completion: June 2027. This is a ClinicalTrials.go
 v estimate\, not a confirmed readout date\, and it can move.\nDrug page: h
 ttps://assetmemo.bio/drug/izalontamab-brengitecan#upcoming-events\nRegistr
 y record: https://clinicaltrials.gov/study/NCT06498986
URL:https://assetmemo.bio/drug/izalontamab-brengitecan#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06787664-2044@assetmemo.bio
DTSTAMP:20261121T005012Z
DTSTART;VALUE=DATE:20270630
DTEND;VALUE=DATE:20270701
SUMMARY:Izalontamab brengitecan: Phase 2 readout est. (NCT06787664)
DESCRIPTION:Izalontamab brengitecan\, phase 2.\nStudy: A Study of BL-B01D1 
 in Patients With Locally Advanced or Metastatic Chordoma\nEstimated primar
 y completion: June 2027. This is a ClinicalTrials.gov estimate\, not a con
 firmed readout date\, and it can move.\nDrug page: https://assetmemo.bio/d
 rug/izalontamab-brengitecan#upcoming-events\nRegistry record: https://clin
 icaltrials.gov/study/NCT06787664
URL:https://assetmemo.bio/drug/izalontamab-brengitecan#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06437522-2044@assetmemo.bio
DTSTAMP:20261121T005012Z
DTSTART;VALUE=DATE:20270630
DTEND;VALUE=DATE:20270701
SUMMARY:Izalontamab brengitecan: Phase 2 readout est. (NCT06437522)
DESCRIPTION:Izalontamab brengitecan\, phase 2.\nStudy: A Study of BL-B01D1+
 PD-1 Monoclonal Antibody in Patients With Recurrent or Metastatic Head and
  Neck Squamous Cell Carcinoma and Other Solid Tumors\nEstimated primary co
 mpletion: June 2027. This is a ClinicalTrials.gov estimate\, not a confirm
 ed readout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/
 izalontamab-brengitecan#upcoming-events\nRegistry record: https://clinical
 trials.gov/study/NCT06437522
URL:https://assetmemo.bio/drug/izalontamab-brengitecan#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06475300-2044@assetmemo.bio
DTSTAMP:20261121T005012Z
DTSTART;VALUE=DATE:20270630
DTEND;VALUE=DATE:20270701
SUMMARY:Izalontamab brengitecan: Phase 2 readout est. (NCT06475300)
DESCRIPTION:Izalontamab brengitecan\, phase 2\, Non-Small Cell Lung Cancer.
 \nStudy: A Study of BL-B01D1+PD-1 Monoclonal Antibody in Patients With Loc
 ally Advanced or Metastatic Non-small Cell Lung Cancer\, Nasopharyngeal Ca
 rcinoma and Other Solid Tumors\nEstimated primary completion: June 2027. T
 his is a ClinicalTrials.gov estimate\, not a confirmed readout date\, and 
 it can move.\nDrug page: https://assetmemo.bio/drug/izalontamab-brengiteca
 n#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT06
 475300
URL:https://assetmemo.bio/drug/izalontamab-brengitecan#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06857175-2044@assetmemo.bio
DTSTAMP:20261121T005012Z
DTSTART;VALUE=DATE:20270630
DTEND;VALUE=DATE:20270701
SUMMARY:Izalontamab brengitecan: Phase 3 readout est. (NCT06857175)
DESCRIPTION:Izalontamab brengitecan\, phase 3\, Urothelial Carcinoma.\nStud
 y: A Study Comparing BL-B01D1 With Chemotherapy of Physician's Choice in P
 atients With Recurrent or Metastatic Urothelial Carcinoma(PANKU-Bladder01)
 \nEstimated primary completion: June 2027. This is a ClinicalTrials.gov es
 timate\, not a confirmed readout date\, and it can move.\nDrug page: https
 ://assetmemo.bio/drug/izalontamab-brengitecan#upcoming-events\nRegistry re
 cord: https://clinicaltrials.gov/study/NCT06857175
URL:https://assetmemo.bio/drug/izalontamab-brengitecan#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06994195-2044@assetmemo.bio
DTSTAMP:20261121T005012Z
DTSTART;VALUE=DATE:20270630
DTEND;VALUE=DATE:20270701
SUMMARY:Izalontamab brengitecan: Phase 3 readout est. (NCT06994195)
DESCRIPTION:Izalontamab brengitecan\, phase 3\, Ovarian Cancer.\nStudy: A S
 tudy Comparing BL-B01D1 With the Investigator's Choice of Chemotherapy in 
 Patients With Platinum-resistant Recurrent Epithelial Ovarian Cancer(PANKU
 -GYN01)\nEstimated primary completion: June 2027. This is a ClinicalTrials
 .gov estimate\, not a confirmed readout date\, and it can move.\nDrug page
 : https://assetmemo.bio/drug/izalontamab-brengitecan#upcoming-events\nRegi
 stry record: https://clinicaltrials.gov/study/NCT06994195
URL:https://assetmemo.bio/drug/izalontamab-brengitecan#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07152405-2282@assetmemo.bio
DTSTAMP:20261121T005012Z
DTSTART;VALUE=DATE:20270630
DTEND;VALUE=DATE:20270701
SUMMARY:Trastuzumab brengitecan: Phase 3 readout est. (NCT07152405)
DESCRIPTION:Trastuzumab brengitecan\, phase 3.\nStudy: A Study of BL-M07D1 
 Versus Investigator's Choice of Chemotherapy in Patients With HER2-positiv
 e Locally Advanced or Metastatic Gastric or Gastro-esophageal Junction Ade
 nocarcinoma\nEstimated primary completion: June 2027. This is a ClinicalTr
 ials.gov estimate\, not a confirmed readout date\, and it can move.\nDrug 
 page: https://assetmemo.bio/drug/trastuzumab-brengitecan#upcoming-events\n
 Registry record: https://clinicaltrials.gov/study/NCT07152405
URL:https://assetmemo.bio/drug/trastuzumab-brengitecan#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05880706-2044@assetmemo.bio
DTSTAMP:20261121T005012Z
DTSTART;VALUE=DATE:20270731
DTEND;VALUE=DATE:20270801
SUMMARY:Izalontamab brengitecan: Phase 2 readout est. (NCT05880706)
DESCRIPTION:Izalontamab brengitecan\, phase 2\, Non-Small Cell Lung Cancer.
 \nStudy: A Study of BL-B01D1 and BL-B01D1 in Combination With Osimertinib 
 Mesylate Tablets in Patients With Locally Advanced or Metastatic Non-small
  Cell Lung Cancer\nEstimated primary completion: July 2027. This is a Clin
 icalTrials.gov estimate\, not a confirmed readout date\, and it can move.\
 nDrug page: https://assetmemo.bio/drug/izalontamab-brengitecan#upcoming-ev
 ents\nRegistry record: https://clinicaltrials.gov/study/NCT05880706
URL:https://assetmemo.bio/drug/izalontamab-brengitecan#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07264816-2282@assetmemo.bio
DTSTAMP:20261121T005012Z
DTSTART;VALUE=DATE:20271231
DTEND;VALUE=DATE:20280101
SUMMARY:Trastuzumab brengitecan: Phase 2 readout est. (NCT07264816)
DESCRIPTION:Trastuzumab brengitecan\, phase 2\, Non-Small Cell Lung Cancer.
 \nStudy: A Study of BL-M07D1 in Combination With Pembrolizumab in Patients
  With Unresectable Locally Advanced or Metastatic HER2-Overexpressing Non-
 Squamous NSCLC\nEstimated primary completion: December 2027. This is a Cli
 nicalTrials.gov estimate\, not a confirmed readout date\, and it can move.
 \nDrug page: https://assetmemo.bio/drug/trastuzumab-brengitecan#upcoming-e
 vents\nRegistry record: https://clinicaltrials.gov/study/NCT07264816
URL:https://assetmemo.bio/drug/trastuzumab-brengitecan#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07730489-2282@assetmemo.bio
DTSTAMP:20261121T005012Z
DTSTART;VALUE=DATE:20271231
DTEND;VALUE=DATE:20280101
SUMMARY:Trastuzumab brengitecan: Phase 3 readout est. (NCT07730489)
DESCRIPTION:Trastuzumab brengitecan\, phase 3\, Colorectal Cancer.\nStudy: 
 A Study Comparing BL-M07D1 With Physician's Choice Therapy in Patients Wit
 h HER2 IHC3+ Advanced Colorectal Cancer Who Failed Prior Treatment With Ox
 aliplatin\, Fluorouracil and Irinotecan\nEstimated primary completion: Dec
 ember 2027. This is a ClinicalTrials.gov estimate\, not a confirmed readou
 t date\, and it can move.\nDrug page: https://assetmemo.bio/drug/trastuzum
 ab-brengitecan#upcoming-events\nRegistry record: https://clinicaltrials.go
 v/study/NCT07730489
URL:https://assetmemo.bio/drug/trastuzumab-brengitecan#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07178795-2282@assetmemo.bio
DTSTAMP:20261121T005012Z
DTSTART;VALUE=DATE:20271231
DTEND;VALUE=DATE:20280101
SUMMARY:Trastuzumab brengitecan: Phase 3 readout est. (NCT07178795)
DESCRIPTION:Trastuzumab brengitecan\, phase 3\, Non-Small Cell Lung Cancer.
 \nStudy: A Study of BL-M07D1 vs Pembrolizumab-platinum Chemotherapy in Fir
 st-line Treatment of HER2-mutant Advanced or Metastatic Non-squamous NSCLC
 \nEstimated primary completion: December 2027. This is a ClinicalTrials.go
 v estimate\, not a confirmed readout date\, and it can move.\nDrug page: h
 ttps://assetmemo.bio/drug/trastuzumab-brengitecan#upcoming-events\nRegistr
 y record: https://clinicaltrials.gov/study/NCT07178795
URL:https://assetmemo.bio/drug/trastuzumab-brengitecan#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06926868-2044@assetmemo.bio
DTSTAMP:20261121T005012Z
DTSTART;VALUE=DATE:20280313
DTEND;VALUE=DATE:20280314
SUMMARY:Izalontamab brengitecan: Phase 2/3 readout est. (NCT06926868)
DESCRIPTION:Izalontamab brengitecan\, phase 2/3.\nStudy: A Study of Izalont
 amab Brengitecan Versus Chemotherapy in Participants With Previously Untre
 ated\, Locally Advanced\, Recurrent Inoperable\, or Metastatic Triple-nega
 tive Breast Cancer Ineligible for Anti-PD(L)1 Drugs (IZABRIGHT-Breast01)\n
 Estimated primary completion: 13 March 2028. This is a ClinicalTrials.gov 
 estimate\, not a confirmed readout date\, and it can move.\nDrug page: htt
 ps://assetmemo.bio/drug/izalontamab-brengitecan#upcoming-events\nRegistry 
 record: https://clinicaltrials.gov/study/NCT06926868
URL:https://assetmemo.bio/drug/izalontamab-brengitecan#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07827261-2044@assetmemo.bio
DTSTAMP:20261121T005012Z
DTSTART;VALUE=DATE:20281231
DTEND;VALUE=DATE:20290101
SUMMARY:Izalontamab brengitecan: Phase 2 readout est. (NCT07827261)
DESCRIPTION:Izalontamab brengitecan\, phase 2\, Non-Small Cell Lung Cancer.
 \nStudy: A Study of BL-B01D1 Combined With Glecirasib in Patients With KRA
 S G12C-Mutated Locally Advanced or Metastatic Non-Small Cell Lung Cancer\n
 Estimated primary completion: December 2028. This is a ClinicalTrials.gov 
 estimate\, not a confirmed readout date\, and it can move.\nDrug page: htt
 ps://assetmemo.bio/drug/izalontamab-brengitecan#upcoming-events\nRegistry 
 record: https://clinicaltrials.gov/study/NCT07827261
URL:https://assetmemo.bio/drug/izalontamab-brengitecan#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07769229-2399@assetmemo.bio
DTSTAMP:20261121T005012Z
DTSTART;VALUE=DATE:20281231
DTEND;VALUE=DATE:20290101
SUMMARY:BL-M09D1: Phase 2 readout est. (NCT07769229)
DESCRIPTION:BL-M09D1\, phase 2.\nStudy: A Study of BL-M09D1 in Patients Wit
 h Locally Advanced or Metastatic Gynecological Malignancies and Other Soli
 d Tumors\nEstimated primary completion: December 2028. This is a ClinicalT
 rials.gov estimate\, not a confirmed readout date\, and it can move.\nDrug
  page: https://assetmemo.bio/drug/bl-m09d1#upcoming-events\nRegistry recor
 d: https://clinicaltrials.gov/study/NCT07769229
URL:https://assetmemo.bio/drug/bl-m09d1#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07837622-2399@assetmemo.bio
DTSTAMP:20261121T005012Z
DTSTART;VALUE=DATE:20281231
DTEND;VALUE=DATE:20290101
SUMMARY:BL-M09D1: Phase 2 readout est. (NCT07837622)
DESCRIPTION:BL-M09D1\, phase 2.\nStudy: A Study of BL-M09D1 in Patients Wit
 h Locally Advanced or Metastatic Urothelial Carcinoma and Other Solid Tumo
 rs\nEstimated primary completion: December 2028. This is a ClinicalTrials.
 gov estimate\, not a confirmed readout date\, and it can move.\nDrug page:
  https://assetmemo.bio/drug/bl-m09d1#upcoming-events\nRegistry record: htt
 ps://clinicaltrials.gov/study/NCT07837622
URL:https://assetmemo.bio/drug/bl-m09d1#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07678957-2282@assetmemo.bio
DTSTAMP:20261121T005012Z
DTSTART;VALUE=DATE:20281231
DTEND;VALUE=DATE:20290101
SUMMARY:Trastuzumab brengitecan: Phase 2 readout est. (NCT07678957)
DESCRIPTION:Trastuzumab brengitecan\, phase 2.\nStudy: A Study Comparing BL
 -M07D1 With DS-8201 in Patients With HR-Positive\, HER2-Low Expressing Rec
 urrent/Metastatic Breast Cancer\nEstimated primary completion: December 20
 28. This is a ClinicalTrials.gov estimate\, not a confirmed readout date\,
  and it can move.\nDrug page: https://assetmemo.bio/drug/trastuzumab-breng
 itecan#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/
 NCT07678957
URL:https://assetmemo.bio/drug/trastuzumab-brengitecan#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07641855-2044@assetmemo.bio
DTSTAMP:20261121T005012Z
DTSTART;VALUE=DATE:20281231
DTEND;VALUE=DATE:20290101
SUMMARY:Izalontamab brengitecan: Phase 2/3 readout est. (NCT07641855)
DESCRIPTION:Izalontamab brengitecan\, phase 2/3.\nStudy: A Study of BL-B01D
 1 Combination Therapy in Patients With Metastatic Castration-resistant Pro
 state Cancer\nEstimated primary completion: December 2028. This is a Clini
 calTrials.gov estimate\, not a confirmed readout date\, and it can move.\n
 Drug page: https://assetmemo.bio/drug/izalontamab-brengitecan#upcoming-eve
 nts\nRegistry record: https://clinicaltrials.gov/study/NCT07641855
URL:https://assetmemo.bio/drug/izalontamab-brengitecan#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07554456-2044@assetmemo.bio
DTSTAMP:20261121T005012Z
DTSTART;VALUE=DATE:20281231
DTEND;VALUE=DATE:20290101
SUMMARY:Izalontamab brengitecan: Phase 2/3 readout est. (NCT07554456)
DESCRIPTION:Izalontamab brengitecan\, phase 2/3\, Esophageal Squamous Cell 
 Carcinoma.\nStudy: A Study of BL-B01D1 in Combination With Tislelizumab ±
 5-Fluorouracil Versus Platinum-Based Chemotherapy Plus Tislelizumab as Fir
 st-line Treatment in Patients With Unresectable\, Locally Advanced Recurre
 nt or Metastatic Esophageal Squamous Cell Carcinoma(PANKU-Esophagus02)\nEs
 timated primary completion: December 2028. This is a ClinicalTrials.gov es
 timate\, not a confirmed readout date\, and it can move.\nDrug page: https
 ://assetmemo.bio/drug/izalontamab-brengitecan#upcoming-events\nRegistry re
 cord: https://clinicaltrials.gov/study/NCT07554456
URL:https://assetmemo.bio/drug/izalontamab-brengitecan#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06891833-2282@assetmemo.bio
DTSTAMP:20261121T005012Z
DTSTART;VALUE=DATE:20281231
DTEND;VALUE=DATE:20290101
SUMMARY:Trastuzumab brengitecan: Phase 2/3 readout est. (NCT06891833)
DESCRIPTION:Trastuzumab brengitecan\, phase 2/3\, HER2-Positive Breast Canc
 er.\nStudy: A Study of BL-M07D1 With or Without Pertuzumab Versus Docetaxe
 l + Carboplatin + Trastuzumab + Pertuzumab in Neoadjuvant Therapy for HER2
 -Positive Breast Cancer\nEstimated primary completion: December 2028. This
  is a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it 
 can move.\nDrug page: https://assetmemo.bio/drug/trastuzumab-brengitecan#u
 pcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT06891
 833
URL:https://assetmemo.bio/drug/trastuzumab-brengitecan#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06838273-2044@assetmemo.bio
DTSTAMP:20261121T005012Z
DTSTART;VALUE=DATE:20281231
DTEND;VALUE=DATE:20290101
SUMMARY:Izalontamab brengitecan: Phase 3 readout est. (NCT06838273)
DESCRIPTION:Izalontamab brengitecan\, phase 3\, Non-Small Cell Lung Cancer.
 \nStudy: A Study of BL-B01D1 in Combination With Osimertinib Versus Osimer
 tinib as First-Line Treatment in Patients With EGFR-Mutated Locally Advanc
 ed or Metastatic Non-Small Cell Lung Cancer(PANKU-Lung04)\nEstimated prima
 ry completion: December 2028. This is a ClinicalTrials.gov estimate\, not 
 a confirmed readout date\, and it can move.\nDrug page: https://assetmemo.
 bio/drug/izalontamab-brengitecan#upcoming-events\nRegistry record: https:/
 /clinicaltrials.gov/study/NCT06838273
URL:https://assetmemo.bio/drug/izalontamab-brengitecan#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07545460-2282@assetmemo.bio
DTSTAMP:20261121T005012Z
DTSTART;VALUE=DATE:20281231
DTEND;VALUE=DATE:20290101
SUMMARY:Trastuzumab brengitecan: Phase 3 readout est. (NCT07545460)
DESCRIPTION:Trastuzumab brengitecan\, phase 3\, Ovarian Cancer.\nStudy: A S
 tudy Comparing BL-M07D1 With Physician's Choice of Chemotherapy in Patient
 s With HER2-Expressing Platinum-Resistant Recurrent Epithelial Ovarian Can
 cer\, Fallopian Tube Cancer\, and Primary Peritoneal Cancer\nEstimated pri
 mary completion: December 2028. This is a ClinicalTrials.gov estimate\, no
 t a confirmed readout date\, and it can move.\nDrug page: https://assetmem
 o.bio/drug/trastuzumab-brengitecan#upcoming-events\nRegistry record: https
 ://clinicaltrials.gov/study/NCT07545460
URL:https://assetmemo.bio/drug/trastuzumab-brengitecan#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07582315-2044@assetmemo.bio
DTSTAMP:20261121T005012Z
DTSTART;VALUE=DATE:20281231
DTEND;VALUE=DATE:20290101
SUMMARY:Izalontamab brengitecan: Phase 3 readout est. (NCT07582315)
DESCRIPTION:Izalontamab brengitecan\, phase 3\, Biliary Tract Cancer.\nStud
 y: A Study Comparing BL-B01D1 With Treatment of Physician's Choice in Pati
 ents With Locally Advanced or Metastatic Biliary Tract Cancer After Failur
 e of Platinum-based Chemotherapy(PANKU-BTC01)\nEstimated primary completio
 n: December 2028. This is a ClinicalTrials.gov estimate\, not a confirmed 
 readout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/iza
 lontamab-brengitecan#upcoming-events\nRegistry record: https://clinicaltri
 als.gov/study/NCT07582315
URL:https://assetmemo.bio/drug/izalontamab-brengitecan#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07648914-2044@assetmemo.bio
DTSTAMP:20261121T005012Z
DTSTART;VALUE=DATE:20281231
DTEND;VALUE=DATE:20290101
SUMMARY:Izalontamab brengitecan: Phase 3 readout est. (NCT07648914)
DESCRIPTION:Izalontamab brengitecan\, phase 3\, HR+/HER2- Metastatic Breast
  Cancer.\nStudy: A Study Comparing BL-B01D1 With Chemotherapy of Physician
 's Choice in Patients With Unresectable Locally Advanced\, Recurrent\, or 
 Metastatic HR+/HER2- Breast Cancer After Failure of Prior Endocrine Therap
 y(PANKU-Breast03)\nEstimated primary completion: December 2028. This is a 
 ClinicalTrials.gov estimate\, not a confirmed readout date\, and it can mo
 ve.\nDrug page: https://assetmemo.bio/drug/izalontamab-brengitecan#upcomin
 g-events\nRegistry record: https://clinicaltrials.gov/study/NCT07648914
URL:https://assetmemo.bio/drug/izalontamab-brengitecan#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07606599-2282@assetmemo.bio
DTSTAMP:20261121T005012Z
DTSTART;VALUE=DATE:20281231
DTEND;VALUE=DATE:20290101
SUMMARY:Trastuzumab brengitecan: Phase 3 readout est. (NCT07606599)
DESCRIPTION:Trastuzumab brengitecan\, phase 3\, Biliary Tract Cancer.\nStud
 y: A Study of BL-M07D1 Versus Physician's Choice of Chemotherapy in Patien
 ts With HER2-expressing Locally Advanced or Metastatic Biliary Tract Cance
 r After Platinum-containing Chemotherapy Failure\nEstimated primary comple
 tion: December 2028. This is a ClinicalTrials.gov estimate\, not a confirm
 ed readout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/
 trastuzumab-brengitecan#upcoming-events\nRegistry record: https://clinical
 trials.gov/study/NCT07606599
URL:https://assetmemo.bio/drug/trastuzumab-brengitecan#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07100080-2044@assetmemo.bio
DTSTAMP:20261121T005012Z
DTSTART;VALUE=DATE:20281215
DTEND;VALUE=DATE:20281216
SUMMARY:Izalontamab brengitecan: Phase 2/3 readout est. (NCT07100080)
DESCRIPTION:Izalontamab brengitecan\, phase 2/3\, Non-Small Cell Lung Cance
 r.\nStudy: Study of Izalontamab Brengitecan (BMS-986507) Versus Platinum-b
 ased Chemotherapy With or Without Amivantamab for EGFR-mutated Non-small C
 ell Lung Cancer After Failure of EGFR TKI Therapy (IZABRIGHT-Lung01)\nEsti
 mated primary completion: 15 December 2028. This is a ClinicalTrials.gov e
 stimate\, not a confirmed readout date\, and it can move.\nDrug page: http
 s://assetmemo.bio/drug/izalontamab-brengitecan#upcoming-events\nRegistry r
 ecord: https://clinicaltrials.gov/study/NCT07100080
URL:https://assetmemo.bio/drug/izalontamab-brengitecan#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06855771-2044@assetmemo.bio
DTSTAMP:20261121T005012Z
DTSTART;VALUE=DATE:20281229
DTEND;VALUE=DATE:20281230
SUMMARY:Izalontamab brengitecan: Phase 2 readout est. (NCT06855771)
DESCRIPTION:Izalontamab brengitecan\, phase 2\, Non-Small Cell Lung Cancer.
 \nStudy: A Study of Navlimetostat (BMS-986504) Alone or in Combination Wit
 h Izalontamab Brengitecan in Participants With Pre-treated Advanced or Met
 astatic Non-small Cell Lung Cancer (NSCLC) With Homozygous MTAP Deletion o
 r MTAP Loss (MountainTAP-9)\nEstimated primary completion: 29 December 202
 8. This is a ClinicalTrials.gov estimate\, not a confirmed readout date\, 
 and it can move.\nDrug page: https://assetmemo.bio/drug/izalontamab-brengi
 tecan#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/N
 CT06855771
URL:https://assetmemo.bio/drug/izalontamab-brengitecan#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07106762-2044@assetmemo.bio
DTSTAMP:20261121T005012Z
DTSTART;VALUE=DATE:20290126
DTEND;VALUE=DATE:20290127
SUMMARY:Izalontamab brengitecan: Phase 2/3 readout est. (NCT07106762)
DESCRIPTION:Izalontamab brengitecan\, phase 2/3\, Urothelial Carcinoma.\nSt
 udy: Phase 2/3 Trial of Izalontamab Brengitecan vs Platinum-based Chemothe
 rapy for Metastatic Urothelial Cancer With Disease Progression on or After
  Immunotherapy\nEstimated primary completion: 26 January 2029. This is a C
 linicalTrials.gov estimate\, not a confirmed readout date\, and it can mov
 e.\nDrug page: https://assetmemo.bio/drug/izalontamab-brengitecan#upcoming
 -events\nRegistry record: https://clinicaltrials.gov/study/NCT07106762
URL:https://assetmemo.bio/drug/izalontamab-brengitecan#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07739186-2044@assetmemo.bio
DTSTAMP:20261121T005012Z
DTSTART;VALUE=DATE:20291231
DTEND;VALUE=DATE:20300101
SUMMARY:Izalontamab brengitecan: Phase 2/3 readout est. (NCT07739186)
DESCRIPTION:Izalontamab brengitecan\, phase 2/3\, Non-Small Cell Lung Cance
 r.\nStudy: A Study Evaluating BL-B01D1 in Combination With a PD-1/VEGF Bis
 pecific Antibody Versus Tislelizumab Plus Platinum-doublet Chemotherapy as
  First-line Treatment for Locally Advanced or Metastatic Non-squamous Non-
 small Cell Lung Cancer(PANKU-Lung06)\nEstimated primary completion: Decemb
 er 2029. This is a ClinicalTrials.gov estimate\, not a confirmed readout d
 ate\, and it can move.\nDrug page: https://assetmemo.bio/drug/izalontamab-
 brengitecan#upcoming-events\nRegistry record: https://clinicaltrials.gov/s
 tudy/NCT07739186
URL:https://assetmemo.bio/drug/izalontamab-brengitecan#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07739199-2044@assetmemo.bio
DTSTAMP:20261121T005012Z
DTSTART;VALUE=DATE:20291231
DTEND;VALUE=DATE:20300101
SUMMARY:Izalontamab brengitecan: Phase 2/3 readout est. (NCT07739199)
DESCRIPTION:Izalontamab brengitecan\, phase 2/3\, Non-Small Cell Lung Cance
 r.\nStudy: A Study Comparing BL-B01D1 in Combination With PD-1/VEGF Bispec
 ific Antibody Versus Chemotherapy in Combination With PD-1/VEGF Bispecific
  Antibody in First-line Patients With Locally Advanced or Metastatic Squam
 ous Non-small Cell Lung Cancer(PANKU-Lung05)\nEstimated primary completion
 : December 2029. This is a ClinicalTrials.gov estimate\, not a confirmed r
 eadout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/izal
 ontamab-brengitecan#upcoming-events\nRegistry record: https://clinicaltria
 ls.gov/study/NCT07739199
URL:https://assetmemo.bio/drug/izalontamab-brengitecan#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07502300-2044@assetmemo.bio
DTSTAMP:20261121T005012Z
DTSTART;VALUE=DATE:20291231
DTEND;VALUE=DATE:20300101
SUMMARY:Izalontamab brengitecan: Phase 3 readout est. (NCT07502300)
DESCRIPTION:Izalontamab brengitecan\, phase 3.\nStudy: A Study Comparing BL
 -B01D1 Combined With Tislelizumab Versus Platinum-containing Chemotherapy 
 Combined With Tislelizumab as First-line Treatment in Patients With Extens
 ive-stage Small Cell Lung Cancer(PANKU-Lung07)\nEstimated primary completi
 on: December 2029. This is a ClinicalTrials.gov estimate\, not a confirmed
  readout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/iz
 alontamab-brengitecan#upcoming-events\nRegistry record: https://clinicaltr
 ials.gov/study/NCT07502300
URL:https://assetmemo.bio/drug/izalontamab-brengitecan#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07729956-2044@assetmemo.bio
DTSTAMP:20261121T005012Z
DTSTART;VALUE=DATE:20291231
DTEND;VALUE=DATE:20300101
SUMMARY:Izalontamab brengitecan: Phase 3 readout est. (NCT07729956)
DESCRIPTION:Izalontamab brengitecan\, phase 3.\nStudy: A Study of BL-B01D1 
 Plus an Anti-PD-1 Antibody Versus Nab-paclitaxel Plus an Anti-PD-1 Antibod
 y in Patients With Previously Untreated\, Locally Advanced\, Inoperable or
  Metastatic Triple-Negative Breast Cancer Whose Tumors Express PD-L1 (PANK
 U-Breast04)\nEstimated primary completion: December 2029. This is a Clinic
 alTrials.gov estimate\, not a confirmed readout date\, and it can move.\nD
 rug page: https://assetmemo.bio/drug/izalontamab-brengitecan#upcoming-even
 ts\nRegistry record: https://clinicaltrials.gov/study/NCT07729956
URL:https://assetmemo.bio/drug/izalontamab-brengitecan#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07518173-2282@assetmemo.bio
DTSTAMP:20261121T005012Z
DTSTART;VALUE=DATE:20291231
DTEND;VALUE=DATE:20300101
SUMMARY:Trastuzumab brengitecan: Phase 3 readout est. (NCT07518173)
DESCRIPTION:Trastuzumab brengitecan\, phase 3\, HER2-Positive Breast Cancer
 .\nStudy: A Study of BL-M07D1 Combined With Pertuzumab Versus Docetaxel Pl
 us Trastuzumab and Pertuzumab in Patients With First-line HER2-positive Re
 current or Metastatic Breast Cancer\nEstimated primary completion: Decembe
 r 2029. This is a ClinicalTrials.gov estimate\, not a confirmed readout da
 te\, and it can move.\nDrug page: https://assetmemo.bio/drug/trastuzumab-b
 rengitecan#upcoming-events\nRegistry record: https://clinicaltrials.gov/st
 udy/NCT07518173
URL:https://assetmemo.bio/drug/trastuzumab-brengitecan#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07797881-2044@assetmemo.bio
DTSTAMP:20261121T005012Z
DTSTART;VALUE=DATE:20301231
DTEND;VALUE=DATE:20310101
SUMMARY:Izalontamab brengitecan: Phase 2 readout est. (NCT07797881)
DESCRIPTION:Izalontamab brengitecan\, phase 2\, Nasopharyngeal Carcinoma.\n
 Study: A Study of BL-B01D1 With or Without PD-1 Monoclonal Antibody in Pat
 ients With High-Risk Locally Advanced Nasopharyngeal Carcinoma\nEstimated 
 primary completion: December 2030. This is a ClinicalTrials.gov estimate\,
  not a confirmed readout date\, and it can move.\nDrug page: https://asset
 memo.bio/drug/izalontamab-brengitecan#upcoming-events\nRegistry record: ht
 tps://clinicaltrials.gov/study/NCT07797881
URL:https://assetmemo.bio/drug/izalontamab-brengitecan#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07640789-2044@assetmemo.bio
DTSTAMP:20261121T005012Z
DTSTART;VALUE=DATE:20301231
DTEND;VALUE=DATE:20310101
SUMMARY:Izalontamab brengitecan: Phase 3 readout est. (NCT07640789)
DESCRIPTION:Izalontamab brengitecan\, phase 3\, Non-Small Cell Lung Cancer.
 \nStudy: A Study Comparing BL-B01D1 in Combination With Osimertinib Versus
  Osimertinib Alone in Patients With Locally Advanced\, Unresectable EGFR-m
 utated Non-small Cell Lung Cancer(Stage III) Whose Disease Has Not Progres
 sed Following Definitive Platinum-based Chemoradiation Therapy(PANKU-Lung0
 8)\nEstimated primary completion: December 2030. This is a ClinicalTrials.
 gov estimate\, not a confirmed readout date\, and it can move.\nDrug page:
  https://assetmemo.bio/drug/izalontamab-brengitecan#upcoming-events\nRegis
 try record: https://clinicaltrials.gov/study/NCT07640789
URL:https://assetmemo.bio/drug/izalontamab-brengitecan#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06618287-2044@assetmemo.bio
DTSTAMP:20261121T005012Z
DTSTART;VALUE=DATE:20310226
DTEND;VALUE=DATE:20310227
SUMMARY:Izalontamab brengitecan: Phase 1/2 readout est. (NCT06618287)
DESCRIPTION:Izalontamab brengitecan\, phase 1/2\, HR+/HER2- Metastatic Brea
 st Cancer.\nStudy: A Study to Evaluate the Safety\, Tolerability\, Drug Le
 vels\, and Preliminary Efficacy of BMS-986507 Combinations in Adult Partic
 ipants With Advanced Solid Tumors\nEstimated primary completion: 26 Februa
 ry 2031. This is a ClinicalTrials.gov estimate\, not a confirmed readout d
 ate\, and it can move.\nDrug page: https://assetmemo.bio/drug/izalontamab-
 brengitecan#upcoming-events\nRegistry record: https://clinicaltrials.gov/s
 tudy/NCT06618287
URL:https://assetmemo.bio/drug/izalontamab-brengitecan#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06830889-2282@assetmemo.bio
DTSTAMP:20261121T005012Z
DTSTART;VALUE=DATE:20311031
DTEND;VALUE=DATE:20311101
SUMMARY:Trastuzumab brengitecan: Phase 3 readout est. (NCT06830889)
DESCRIPTION:Trastuzumab brengitecan\, phase 3\, HER2-Positive Breast Cancer
 .\nStudy: A Study of BL-M07D1 Versus T-DM1 in the Adjuvant Treatment of HE
 R2-positive Breast Cancer With Residual Invasive Cancer After Neoadjuvant 
 Therapy\nEstimated primary completion: October 2031. This is a ClinicalTri
 als.gov estimate\, not a confirmed readout date\, and it can move.\nDrug p
 age: https://assetmemo.bio/drug/trastuzumab-brengitecan#upcoming-events\nR
 egistry record: https://clinicaltrials.gov/study/NCT06830889
URL:https://assetmemo.bio/drug/trastuzumab-brengitecan#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07680790-2044@assetmemo.bio
DTSTAMP:20261121T005012Z
DTSTART;VALUE=DATE:20311230
DTEND;VALUE=DATE:20311231
SUMMARY:Izalontamab brengitecan: Phase 3 readout est. (NCT07680790)
DESCRIPTION:Izalontamab brengitecan\, phase 3\, Non-Small Cell Lung Cancer.
 \nStudy: Study of Izalontamab Brengitecan (BMS-986507) in Combination With
  Osimertinib Versus Osimertinib Monotherapy or Osimertinib in Combination 
 With Platinum-based Chemotherapy for EGFRmt Non-small Cell Lung Cancer (IZ
 ABRIGHT-Lung02)\nEstimated primary completion: 30 December 2031. This is a
  ClinicalTrials.gov estimate\, not a confirmed readout date\, and it can m
 ove.\nDrug page: https://assetmemo.bio/drug/izalontamab-brengitecan#upcomi
 ng-events\nRegistry record: https://clinicaltrials.gov/study/NCT07680790
URL:https://assetmemo.bio/drug/izalontamab-brengitecan#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07642024-2044@assetmemo.bio
DTSTAMP:20261121T005012Z
DTSTART;VALUE=DATE:20321231
DTEND;VALUE=DATE:20330101
SUMMARY:Izalontamab brengitecan: Phase 2/3 readout est. (NCT07642024)
DESCRIPTION:Izalontamab brengitecan\, phase 2/3\, Non-Small Cell Lung Cance
 r.\nStudy: A Study of BL-B01D1 in Combination With Osimertinib as Perioper
 ative Therapy in Patients With EGFR-mutated Resectable Non-small Cell Lung
  Cancer(PANKU-Lung09)\nEstimated primary completion: December 2032. This i
 s a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it ca
 n move.\nDrug page: https://assetmemo.bio/drug/izalontamab-brengitecan#upc
 oming-events\nRegistry record: https://clinicaltrials.gov/study/NCT0764202
 4
URL:https://assetmemo.bio/drug/izalontamab-brengitecan#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07783321-2044@assetmemo.bio
DTSTAMP:20261121T005012Z
DTSTART;VALUE=DATE:20331231
DTEND;VALUE=DATE:20340101
SUMMARY:Izalontamab brengitecan: Phase 3 readout est. (NCT07783321)
DESCRIPTION:Izalontamab brengitecan\, phase 3\, Nasopharyngeal Carcinoma.\n
 Study: A Study of Anti-PD-1 Antibody With or Without BL-B01D1 as Maintenan
 ce Therapy Following Anti-PD-1 Antibody Plus Chemotherapy for the First-li
 ne Treatment of Recurrent or Metastatic Nasopharyngeal Carcinoma (PANKU-NP
 C02)\nEstimated primary completion: December 2033. This is a ClinicalTrial
 s.gov estimate\, not a confirmed readout date\, and it can move.\nDrug pag
 e: https://assetmemo.bio/drug/izalontamab-brengitecan#upcoming-events\nReg
 istry record: https://clinicaltrials.gov/study/NCT07783321
URL:https://assetmemo.bio/drug/izalontamab-brengitecan#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
END:VCALENDAR
